This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Addenbrooke’s Cognitive Examination validation in Parkinson’s disease


Reyes, M. A., Perez-Lloret, S., Roldan Gerschcovich, E., Martin, M. E., Leiguarda, R., Merello, M.


European Journal Of Neurology: The Official Journal Of The European Federation Of Neurological Societies, Volume: 16, No.: 1, Pages.: 142-147

Year of Publication



Background: There is a clear need for brief, sensitive and specific cognitive screening instruments in Parkinson’s disease (PD).; Objectives: To study Addenbrooke’s Cognitive Examination (ACE) validity for cognitive assessment of PD patient’s using the Mattis Dementia Rating Scale (MDRS) as reference method. A specific scale for cognitive evaluation in PD, in this instance the Scales for Outcomes of Parkinson’s disease-Cognition (SCOPA-COG), as well as a general use scale the Mini-mental state examination (MMSE) were also studied for further correlation.; Methods: Forty-four PD patients were studied, of these 27 were males (61%), with a mean (SD) age of 69.5 (11.8) years, mean (SD) disease duration of 7.6 (6.4) years (range 1-25), mean (SD) total Unified Parkinson’s Disease Rating Scale (UPDRS) score 37 (24) points, UPDRS III 16.5 (11.3) points. MDRS, ACE and SCOPA-COG scales were administered in random order. All patients remained in on-state during the study.; Results: Addenbrooke’s Cognitive Examination correlated with SCOPA-COG (r = 0.93, P < 0.0001), and MDRS (r = 0.91 P < 0.0001) and also with MMSE (r = 0.84, P < 0.001). Area under the receiver-operating curve, taking MDRS as the reference test, was 0.97 [95% confidence interval (CI): 0.92-1.00] for ACE, 0.92 (95% CI: 0.83-1.00) for SCOPA-COG and 0.91 (95% CI: 0.83-1.00) for MMSE. Best cut-off value for ACE was 83 points [Sensitivity (Se) = 92%; Specificity (Sp) = 91%; Kappa concordance (K) = 0.79], 20 points for the SCOPA-COG (Se = 92%; Sp = 87%; K = 0.74) and 26 points for MMSE (Se = 61%; Sp = 100%; K = 0.69).; Conclusion: Addenbrooke's Cognitive Examination appears to be a valid tool for dementia evaluation in PD, with a cut-off point which should probably be set at 83 points, displaying good correlation with both the scale specifically designed for cognitive deficits in PD namely SCOPA-COG, as well as with less specific tests such as MMSE.;

Bibtex Citation

@article{Reyes_2009, doi = {10.1111/j.1468-1331.2008.02384.x}, url = {}, year = 2009, month = {jan}, publisher = {Wiley-Blackwell}, volume = {16}, number = {1}, pages = {142--147}, author = {M. A. Reyes and S. P. Lloret and E. R. Gerscovich and M. E. Martin and R. Leiguarda and M. Merello}, title = {Addenbrooke's Cognitive Examination validation in Parkinson's disease}, journal = {European Journal of Neurology} }


aged, aged, 80 and over, cognition disorders, cohort studies, complications, diagnosis, diagnosis, differential, etiology, female, humans, lewy body disease, male, methods, middle aged, neurologic examination, neuropsychological tests, parkinson disease, physiopathology, standards

Countries of Study


Types of Dementia

Parkinson’s Dementia

Types of Study

Instrument development and testing (cross walking of measures, etc.)

Type of Interventions

Diagnostic Target Identification

Diagnostic Targets

Cognition testing (inc. task driven tests such as clock drawing)